
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Shares | 95.940 | 95.940 | 0.000 |
Bonds | 0.180 | 0.180 | 0.000 |
Convertible | 0.160 | 0.160 | 0.000 |
Preferred | 3.680 | 3.680 | 0.000 |
Other | 0.070 | 0.170 | 0.100 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 20.853 | 20.853 |
Price to Book | 4.300 | 4.300 |
Price to Sales | 2.078 | 2.078 |
Price to Cash Flow | 18.525 | 18.525 |
Dividend Yield | 0.721 | 0.721 |
5 Years Earnings Growth | 10.431 | 10.431 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.930 | 99.930 |
Financial Services | 0.070 | 0.070 |
Number of long holdings: 270
Number of short holdings: 2
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 10.27 | 818.02 | -2.61% | |
UnitedHealth | US91324P1021 | 6.21 | 425.33 | -6.34% | |
Intuitive Surgical | US46120E6023 | 5.88 | 468.32 | -2.99% | |
Thermo Fisher Scientific | US8835561023 | 4.61 | 421.85 | -1.32% | |
Stryker | US8636671013 | 4.23 | 339.59 | -1.99% | |
Danaher | US2358511028 | 3.77 | 184.96 | -1.00% | |
argenx ADR | US04016X1019 | 3.72 | 595.70 | -0.08% | |
Merck&Co | US58933Y1055 | 2.55 | 77.85 | -0.19% | |
Boston Scientific | US1011371077 | 2.54 | 93.58 | -1.62% | |
Vertex | US92532F1003 | 2.42 | 477.52 | -2.37% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
TD Dividend Growth I | 10.45B | -1.45 | 4.64 | 7.19 | ||
TD Dividend Growth F | 10.45B | -1.18 | 5.85 | 8.41 | ||
TD Dividend Growth S | 10.45B | -1.17 | 5.84 | 8.47 | ||
TD Dividend Growth Fund Premium F | 10.45B | -1.17 | 5.89 | 8.47 | ||
TD Dividend Growth Fund Premium s | 10.45B | -1.45 | 4.70 | 7.25 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review